Inci, FatihKaratas, Fatih2024-09-292024-09-2920191107-06252241-6293https://hdl.handle.net/20.500.14619/8621Purpose: Paclitaxel has been associated with serum aminotransferase elevations, however, paclitaxel induced hepatosteatosis has not been evaluated systematically. This study assessed the rate of paclitaxel-related hepatosteatosis. Methods: Forty one early breast cancer (BC) patients were included the study. Hepatic ultrasonograpy, demographic features and biochemical liver function tests before and after 12 weeks of paclitaxel were assessed. Results: New-onset hepatosteatosis was developed in 26.7% of the patients. Baseline triglyceride>200mg/dL (OR, 11.25; p=0.015), LDH at baseline > 191.48 IU/L (OR, 4.93; p=0.048), and total bilirubin >0.51 mg/dL after paditaxel (OR, 6.17; p=0.042) were found as independent prognostic markers for new-onset hepatosteatosis. Conclusion: Paclitaxel may induce hepatosteatosis in patients with BC.eninfo:eu-repo/semantics/closedAccesspaclitaxelhepatosteatosisbreast cancerArticle2360631983106235524WOS:000503405400022Q4